Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Balyasny Asset Management Ups Stake In NuStar Energy L.P. (NS)

Dmitry Balyasny is bullish on NuStar Energy L.P. (NYSE:NS) and has increased his holding of the stock. In a recent filing with the Securities and Exchange Commission, Balyasny Asset Management has revealed the addition of 1.64 million shares to its previous position. As a result, the fund now holds 3.95 million shares, which account for approximately 5.07% of the company’s common stock.

Dmitry Balyasny

Hedge fund guru Jim Simons is also very bullish on NuStar Energy L.P. (NYSE:NS) having increased his stake in the company by roughly 200% during the first quarter of 2014. In its latest 13F filing, Renaissance Technologies reported ownership of approximately 504,100 shares. David Kowitz and Sheldon Kasowitz, the managers of Indus Capital, are also optimistic about the prospects of the company and have boosted their stake by 30% to 650,000 shares during the first three months of this year. Richard Driehaus likes NuStar Energy L.P. (NYSE:NS) as well and has initiated a position for his fund, Driehaus Capital, during the first quarter, amassing 95,600 shares.

Disclousre: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!